Statement: Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.
Primary_evidence: Inclusion Criteria:   Patient is an adult,  18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines   Women and men with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.   Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive and HER2-negative breast cancer by local laboratory. Local pathology is sufficient for assessment.   Patient must have either:   Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria ).   Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease   Non-measurable disease   Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 2   Exclusion Criteria   Patient who received any CDK4/6 inhibitor or any mTOR inhibitor.   Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole   Patients with current inflammatory breast cancer.   Patient has received > 1 chemotherapy for the treatment of advanced/metastatic breast cancer   Patient has received > 2 endocrine therapies for the treatment of advanced/metastatic breast cancer   Patient has central nervous system (CNS) involvement. If patient is fulfilling the following 3 criteria she/he is eligible for the trial.   completed prior therapy (including radiation and/or surgery) for CNS metastases  28 days prior to the start of study and   CNS tumor is clinically stable at the time of screening and   Patient is not receiving steroids and enzyme inducing anti-epileptic medications for brain metastases   Patient has active cardiac disease or a history of cardiac dysfunction
Secondary_evidence: Inclusion Criteria:   Stage 1-2 invasive breast cancer diagnosis,   DCIS   Ability to read English Exclusion Criteria: Male